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O lisossoma é um organelo celular que degrada macromoléculas. As doenças 
de sobrecarga lisossomal (DSL) surgem quando há acumulação destas no 
lisossoma devido principalmente a defeitos genéticos em hidrolases 
lisossomais. A doença de Fabry é uma DSL causada por mutações no gene 
GLA que codifica a hidrolase α-Galactosidase A. O lisossoma é importante no 
processo de apresentação de antigénios lipídicos às células T. A apresentação 
de antigénios lipídicos é mediada pelas moléculas CD1 existentes nas células 
apresentadoras de antigénios, que se associam aos antigénios lipídicos 
formando complexos que são capazes de activar células T que respondem às 
moléculas de CD1 (células T restritas a CD1). Existem cinco isoformas de CD1 
(a,b,c,d,e), mas somente quatro delas (a,b,c,d) apresentam antigénios. O 
tráfego intracelular destas quatro isoformas é diferente. Um dos locais em que 
há associação das moléculas de CD1 aos antigénios lipídicos é o lisossoma, 
sendo esperado que o processo de apresentação de antigénios lipídicos e 
consequente activação das células T restritas a CD1 estejam afectados nas 
DSL. Em vários modelos animais de DSL, incluindo a doença de Fabry, foi 
observada uma redução na percentagem de um tipo de células restritas a 
CD1d (células iNKT) e também na capacidade de apresentação de antigénios 
lipídicos. Em humanos, estudos anteriores não encontraram alterações na 
percentagem das células iNKT em doentes de Gaucher e de Fabry. No 
entanto, a capacidade de apresentação de antigénios lipídicos em doentes 
com DSL não foi ainda analisada. Neste estudo, analisámos as células iNKT e 
suas subpopulações e a capacidade de apresentação de antigénios lipídicos 
de doentes de Fabry. Não foram encontradas alterações na percentagem de 
células iNKT entre doentes e controlos. Em humanos, as células iNKT podem 
ser divididas em três subpopulações que produzem diferentes tipos de 
citocinas de acordo com a expressão de CD4 e CD8: as células iNKT que só 
expressam CD4 (CD4+) produzem citocinas Th1 e Th2, as células iNKT que 
não expressam nenhuma das moléculas (DN) produzem essencialmente Th1 e 
as células iNKT que só expressam CD8 produzem principalmente IFN-γ. Neste 
estudo, detectou-se uma redução na percentagem das células iNKT CD4+ em 
doentes de Fabry, quando comparados com controlos. Cinco doentes foram 
testados relativamente à capacidade de apresentação de antigénios lipídicos 
através de duas moléculas de CD1 (b,d). Não foram encontradas alterações na 
capacidade de apresentar o antigénio sulfatídio através da molécula CD1b. 
Curiosamente, a apresentação do antigénio GM1 por CD1b estava reduzida 
em dois doentes. Dois doentes tinham reduzida capacidade de apresentar o 
antigénio sulfatídio através de CD1d. Concluindo, há uma alteração nas 
subpopulações das células iNKT em doentes de Fabry, que pode estar 
associada a modificações no perfil de citocinas produzido, contribuindo para a 
patologia da doença. Pela primeira vez foram realizados ensaios de 
apresentação de antigénios lipídicos em doentes com DSL, mas são 
necessários mais estudos para tirar mais conclusões.   
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abstract 
 
The lysosome is a cellular organelle responsible for the degradation of 
macromolecules. Lysosomal storage diseases (LSDs) arise from the 
accumulation of undegraded macromolecules in the lysosome, mainly due to 
genetic defects in the lysosomal hydrolases. Fabry disease is a LSD caused by 
mutations in the GLA gene which codifies the enzyme α-Galactosidase A, a 
lysosomal hydrolase responsible for globotriaosilceramide degradation. The 
lysosome is also a key player in the process of lipid antigen presentation to T 
cells. Lipid antigen presentation is mediated by CD1 molecules existent in 
antigen presenting cells (APCs), which associate with lipid antigens, forming 
complexes that are able to activate T cells responsive to CD1 molecules (CD1-
restricted T cells). There are five isoforms of CD1 molecules (a,b,c,d,e), but 
only four of them (a,b,c,d) present lipid antigens to T cells. The four isoforms 
have different intracellular trafficking patterns. One of the places where 
association of lipid antigens with CD1 molecules occurs is the lysosome. 
Therefore, it was hypothesized that the process of lipid antigen presentation 
and consequent activation of CD1-restricted T cells is impaired in LSDs. 
Several mouse models of LSDs, including Fabry disease, were already shown 
to have reduced frequencies of a specific type of CD1d-restricted T cells (iNKT 
cells) and decreased capacity of lipid antigen presentation. In humans, 
previous studies have found no alterations in iNKT cell percentage in patients 
of two different LSDs: Gaucher and Fabry diseases. Studies assessing the 
efficiency of lipid antigen presentation in LSD patients are missing. In this 
study, we analysed the iNKT cells and iNKT cell subsets and the capacity of 
lipid antigen presentation of Fabry disease patients. We found no differences in 
percentage of iNKT cells between Fabry disease and control subjects. In 
humans, iNKT cells can be divided in three subsets that produce different types 
of cytokines according to CD4 and CD8 expression: iNKT cells expressing only 
CD4 (CD4+) produce Th1 and Th2 cytokines, iNKT cells that do not express 
both molecules (DN) produce mainly Th1 and iNKT cells that only express CD8 
(CD8+) produce mostly IFN-γ. In this study, we found a reduction in iNKT CD4+ 
subset in Fabry disease patients when compared to control subjects. In lipid 
antigen presentation assays, five patients were tested for the capacity of their 
dendritic cells to present lipid antigens by two CD1 molecules: CD1b and d. We 
found no alterations in patients’ capacity to present the lipid antigen sulfatide by 
CD1b. Interestingly, presentation of the lipid antigen GM1 by CD1b was 
reduced in two patients. Regarding CD1d molecules, two patients had reduced 
capacity of presenting sulfatide when compared to control subjects. 
Concluding, we found an imbalance in the iNKT cell subsets in Fabry disease 
patients that can be associated with an alteration in cytokine profile which might 
contribute to disease pathology. Lipid antigen presentation assays were for the 
first time performed in LSDs patients, but more studies are needed to take 
further conclusions.  
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1. Introduction 
 
1.1 Lysosomal storage diseases 
 
The lysosome is an acidic organelle that contains several hydrolases involved in the 
degradation of macromolecules from either intracellular or extracellular sources [1]. 
Lysosomal storage diseases (LSDs) are a group of inherited metabolic diseases 
characterized by the accumulation in the lysosome of non-metabolized macromolecules. 
These substances accumulate mostly due to mutations in the lysosomal hydrolases [1]. 
However, mutations in proteins involved in lipid transport, vesicular trafficking and 
biogenesis of lysosomes were also associated with LSDs [1]. The substrate accumulation 
in the lysosome is progressive and eventually leads to impaired cell and organ function. 
Consequently, LSDs tend to worse with age, leading often do early death. LSDs 
individually are considered rare, but there are few studies reporting their prevalence. A 
study in Australia has found that LSDs frequency in this country was of 1 in 7700 live 
births [2]. In Netherlands, a frequency of LSDs of 1 in 7143 live births was reported [3]. A 
study performed in Portugal found higher frequency of LSDs than the other two, with an 
incidence of 1 in 4000 live births [4].  
LSDs can be classified according to the biochemical nature of the stored material 
into lipidoses (mainly sphingolipidoses), mucopolysaccharidoses (MPSs), glycogenoses, 
glycoproteinoses, neuronal ceroid lipofuscinosis and mucolipidoses [5].    
The first recognized LSD was Pompe disease, which is characterized by the 
accumulation of glycogen in the lysosome. It was initially described in 1932, prior to the 
discovery of the lysosome. In 1963, this glycogen storage disease was associated with a 
defect in the lysosomal enzyme α-glucosidase [6].  
Most of the first described LSDs were sphingolipidosis, which include Gaucher, 
Niemann-Pick, Tay-Sachs, Sandhoff and Fabry diseases [5]. These diseases were initially 
called lipidosis, due to the high amount of lipids present in the patients’ serum. The 
enzymatic defects that lead to the diverse sphingolipidoses and the main substrates that are 
accumulated are described in Table 1.  
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Table 1. Sphingolipidoses: defective enzyme and accumulated substrates. 
Disease Defective enzyme Accumulated substrates 
 
GM1 gangliosidosis 
 
β-galactosidase 
 
GM1 ganglioside, oligosaccharides 
and glycoproteins with a terminal β-
galactosidic linkage 
GM2 gangliosidosis  
 
 
• Tay-Sachs disease β-hexosaminidase A GM2 ganglioside 
• Sandhoff disease β-hexosaminidase A and B GM2 ganglioside, GA2 ganglioside, 
oligosaccharides and glycoproteins 
with a terminal β-N-
acetylglucosamine linkage 
Fabry disease α-galactosidase A  Globotriaosylceramide 
Metachromatic 
leukodystrophy 
Arylsulfatase A Sulfatide 
Krabbe disease Galactosylceramidase Galactocerebroside, psychosine 
Gaucher disease Glucosylceramidase Glucocerebroside 
Niemann-Pick disease 
types A and B 
Sphingomyelinase Shingomyelin 
Farber disease Ceramidase Ceramide 
 
The focus of this study is Fabry disease, which is described in the following 
section.  
 
1.1.1 Fabry disease 
 
Fabry disease is an X-linked recessive LSD which arises due to a mutation in the 
GLA gene. The GLA gene encodes the lysosomal enzyme α-galactosidase A (α-Gal A), 
responsible for the hydrolysis of the terminal galactose of the glycosphingolipid 
globotriaosylceramide (Gb3). As degradation of this lipid is compromised, it accumulates 
in the lysosomes of deficient cells. The deposits occur in several cells, but more 
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prominently in endothelial and perithelial cells, cells from the smooth muscle of the blood 
vessels, cornea epithelial cells, glomeruli and renal tubes, muscle fibres of the heart and 
ganglionic cells of the autonomous nervous system [7]. 
 
Molecular basis  
The gene that codifies for α-Gal A (GLA gene) is localized in a region of the long 
arm of the X chromosome, Xq22. It has a length of 12kb and comprises seven exons [7]. 
To date, there are more than five hundred described mutations in the Human Gene 
Mutation Database, including missense and nonsense mutations, deletions, insertions, 
indels, rearrangements and splicing mutations, with the first two alterations being the most 
common. These mutations are scattered by all seven exons [8].  
The mature α-Gal A is a homodimer composed by two monomers with 398 residues 
each. Its initial size is 429 aminoacids, but this includes a signal sequence that directs the 
protein to the lysosome and is then removed. Mutations have been described for nearly half 
of the residues of this enzyme. Interestingly, structural studies have shown that only 10% 
of Fabry disease causing mutations are located near the active site of the enzyme, while 
65% of them occur in buried aminoacid residues [8]. This indicates that in most of the 
cases, the reduced activity is related to misfolding of the enzyme.  
α-Gal A is glycosylated in the Golgi apparatus, a central process for the enzyme 
function, but also for its stability. There are three residues that can be glycosylated: N139, 
N192 and N215. Mutational studies in these residues showed that lack of glycosylation in 
the position 215 led to a reduction of approximately 50% of enzymatic activity [7]. The 
glycosylation at this site is essential for correct protein folding but also for traffic to the 
lysosome. Consistent with these findings, hemyzigotes who have the missense mutation 
N215S present residual α-Gal A activity, mainly associated with cardiac manifestations 
[7]. Other mutations were found to be related to specific clinical phenotypes. For example, 
the mutation M42L was reported in a patient that presented only renal manifestations of 
Fabry disease [9]. The efforts to establish a genotype/phenotype correlation in Fabry 
disease proceed with studies of sequence conservation, to identify the key residues for 
protein function [8].  
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Clinical Manifestations 
Clinical onset typically occurs during childhood or adolescence, but in certain 
disease variations it can be delayed to adulthood. The first symptoms to arise during 
childhood are usually pain in the extremities (acroparesthesias), fever of unknown origin, 
reduced sweating (hypohidrosis) and gastrointestinal manifestations [10]. Because these 
symptoms are not specific, the disease is hard to diagnose in this phase. In late adolescence 
more particular symptoms appear, namely skin lesions (angiokeratoma) and corneal 
opacity [10]. Between the third and fifth decade of life, renal and cardiac problems emerge, 
leading to decreased life expectancy. Cerebrovascular complications such as stroke are also 
frequent in Fabry disease [10]. Acroparesthesias are one of the most incapacitating 
symptoms of Fabry disease. This pain can be constant or appear in the form of crises with 
variable duration. At the cellular level, this symptom is believed to be caused by a small 
fibre neuropathy, which is also responsible by decreased sensitivity to cold and warm as 
well as heat pain [10]. Angiokeratomas are a characteristic of Fabry disease, but they can 
be absent in some disease variants. They arise due to vascular dysfunction and tend to 
increase in number and size with age [7]. The main gastrointestinal manifestations are 
diarrhea and abdominal pain. At the cardiac level, Fabry disease patients might present 
hypertrophic cardiomyopathy, valvular disease, conduction defects and arrhythmia [7, 10]. 
Other manifestations that have been reported include respiratory problems, some bone 
deformities, lymphadenopathy, anemia and delayed growth [10]. 
While some patients present a classical Fabry disease phenotype characterized by 
angiokeratoma, corneal opacities and acroparesthesias, there are other variants in which 
these symptoms are absent. In these variants there is usually a significant residual activity 
of α-Gal A and lower deposition of glycosphingolipids in the tissues [7]. One example is 
the cardiac variant, which appears later in life and with manifestations confined to cardiac 
function. Similarly, there are some cases in which only the kidney is affected [7]. The 
discovery of such variants highlighted the need for inclusion of Fabry disease in the 
differential diagnosis of patients with cardiac and renal disease of unknown origin.  
Fabry disease can also be present in women with only one defective allele 
(heterozygous), but usually the symptoms appear later and with different degrees of 
severity. However, there were reported cases of women presenting a phenotype as severe 
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as that of classically affected males [7]. This variability occurs due to X-chromosome 
random inactivation [7]. 
 
Diagnosis and treatment 
The clinical suspicion for Fabry disease usually occurs when angiokeratoma and 
corneal dystrophy are present [7]. After clinical evaluation, biochemical and genetic tests 
must be made to confirm the suspicious cases. In men, if the classical phenotype is present, 
α-Gal A activity is very low or absent, and usually the biochemical diagnosis is sufficient 
to identify Fabry disease patients. However, in atypical cases, enzymatic activity can reach 
35% of the normal values [7]. When low activity of α-Gal A is detected, the molecular 
diagnosis is performed to identify the specific mutation responsible for the disease. Due to 
X-chromosome random inactivation, women can present normal values of α-Gal A 
activity. Therefore, the biochemical diagnosis is not sufficient to exclude the presence of 
Fabry disease in women. Thus, the molecular diagnosis is essential for the identification of 
female Fabry disease patients. The molecular diagnosis is done by denaturing high 
performance liquid chromatography, used as a screening method, followed by gene 
sequencing to identify the specific mutation [11, 12]. 
Treatment for Fabry disease is available since 2001, when enzyme replacement 
therapy (ERT) was introduced. There are two enzymes available: algasidase α (Replagal, 
Shire HGT) and algasidase β (Fabrazyme, Genzyme). Their primary structure is identical 
but there are variations in the glycosylation pattern [13]. However, pre-clinical and clinical 
trials have shown that both enzymes have similar efficiency. ERT was shown to decrease 
the plasma levels of Gb3 accumulation within three months of treatment [14]. There is an 
overall improvement in quality of life, with a reduction in pain and a delay in the decline of 
renal and cardiovascular functions [7].  
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1.2 Lipid antigen presentation 
 
T cells are classically known by their ability to recognize protein antigens. 
However, T cells are also able to recognize lipids. As for proteins, lipid antigens cannot be 
directly recognized by T cells. Therefore, they need to be presented by antigen presenting 
cells (APCs) such as dendritic cells. At the APC surface, CD1 molecules loaded with lipid 
antigens interact with the T cell receptor (TCR) of specific T cells. This interaction causes 
T cell activation. 
 
1.2.1. CD1 molecules 
 
CD1 molecules are composed by a heavy chain, the α chain, and a light chain, β2 
microglobulin. The heavy chain is a transmembranar chain with three extracellular 
domains: the membrane distal α1 and α2 and the membrane proximal α3.  The α3 domain 
is responsible for the non-covalent binding to β2 microglobulin (Figure 1).  
 
Figure 1. Crystal structure of CD1d associated with α-Galactosylceramide (α-GalCer). From [15]. 
 
CD1 expression 
In humans there are five isoforms of CD1 α chain (a, b, c, d, e) codified by five 
different genes located in chromosome 1, while in mice there is only one isoform, CD1d, 
codified by two genes in chromosome 3 [15]. The β2 microglobulin is codified by a gene 
in the human chromosome 15 [16]. The CD1 isoforms can be divided in three groups 
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according to homology of the α1 and α2 domains: group I includes CD1a, b and c; group II 
is composed by CD1d and group III by CD1e [17]. Group I CD1 molecules are expressed 
in thymocytes, dendritic cells and Langerhans cells [18]. The expression of CD1c but not 
CD1a or CD1b molecules on marginal zone B cells and in 50% of peripheral blood B cells 
was also described [19]. Monocytes lack expression of all group I CD1 molecules. 
Conversely, CD1d has a broader expression pattern and it is present in most of the cells 
with hematopoietic origin, with higher levels in dendritic cells, B cells and monocytes. 
CD1d is also expressed in other cell types, like keratinocytes, hepatocytes, intestinal 
epithelial cells, hair follicles and Schwann cells [15]. Group I CD1 molecules expression is 
upregulated by GM-CSF (granulocyte macrophage colony stimulating factor) during in 
vitro dendritic cell differentiation from monocytes [18]. On the contrary, during in vitro 
differentiation there is a reduction in CD1d expression [20]. CD1e is mainly expressed in 
dendritic cells [21]. 
 
Synthesis and Trafficking 
To understand lipid antigen presentation it is important to know how CD1 
molecules bind to lipids and reach cell surface to interact with lipid specific CD1-restricted 
T cells. In the endoplasmic reticulum (ER), CD1 proteins are synthesized and its 
glycosylation is initiated. After this process, CD1 α chain binds in a non-covalent manner 
to β2 microglobulin [15]. Protein folding is facilitated by the chaperones calreticulin and 
calnexin and by the thiol oxidoreductase ERp57 [21]. Still in the ER, endogenous lipids 
bind CD1 molecules and probably prevent their collapse [21]. It is not fully understood 
how these lipids are loaded onto CD1 molecules, but some studies showed that microsomal 
triglyceride transfer protein (MTP) plays a key role in this process [22-25]. This protein 
was previously known for its role in the loading of triglycerides, phospholipids and 
cholesterol esters onto apolipoprotein B. Initially, MTP was identified as an important 
protein for activation of CD1d restricted T cells. The gene that codifies MTP was deleted 
in hepatocytes and silenced in intestinal epithelial cells. This resulted in impaired lipid 
antigen presentation to a CD1d restricted T cell clone [22]. Later, it was shown in vitro that 
MTP is expressed in APCs, such as mouse liver mononuclear cells and mouse and human 
B cell lines and is able to directly transfer phospholipids to recombinant CD1d [23]. It was 
also found that spleen and bone marrow derived dendritic cells in which MTP is absent had 
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reduced ability to present antigens by CD1d. In a posterior study, monocyte-derived 
dendritic cells were cultured with an inhibitor of MTP, which led to a substantial decrease 
in antigen presentation by CD1a, b and c [24], indicating that MTP is important for both 
group I and II CD1 molecules. More recently, patients with a genetic defect in MTP were 
studied for immunological alterations. It was found that these patients presented defects in 
lipid antigen presentation by both group I and group II CD1 molecules, reinforcing the 
importance of MTP in the process of CD1 molecules maintenance [25]. 
Properly assembled CD1 molecules move from the ER to the Golgi apparatus, 
where the glycosylation process is completed. Then, CD1 molecules follow the secretory 
pathway to the plasma membrane, with exception of CD1e. This isoform does not reach 
the plasma membrane surface and therefore is not capable of presenting antigens [17]. In 
immature dendritic cells, CD1e accumulates in the Golgi apparatus after synthesis [26]. 
After dendritic cell maturation, it migrates to the late endossome and then to the lysosome, 
where it is cleaved to a more stable soluble form [26]. In the lysosome, CD1e is involved 
in lipid loading on CD1b [27]. CD1d can be sent to the plasma membrane directly or bind 
the invariant chain (li) or MHC class II/li complexes and be directed to the lysosome after 
synthesis [15, 28, 29]. In humans, the presentation of non-self antigens (microbial or 
environmental) or self-antigens (produced by the organism) by the CD1d molecule occurs 
by different mechanisms. While the presentation of some non-self antigens seems to need 
CD1d internalization and lipid lysosomal processing, self antigens appear to be presented 
even in the absence of CD1d internalization [30]. Furthermore, MHCII/li complex 
association with CD1d facilitates the non-self antigen presentation, but appears to have no 
effect on self-reactivity. 
In the plasma membrane, CD1 isoforms present some potent antigens (ex.: α-
galactosylceramide) that bind directly to CD1 at the cell surface, or are internalized and 
follow the endocytic recycling pathway. Each CD1 isoform presents different trafficking 
pathways and distribution patterns (Figure 2). CD1b, CD1c and CD1d internalization 
occurs by the interaction of tyrosine motifs in their cytoplasmatic tails with the adaptor 
protein complex AP-2 [15, 31]. This complex allows the internalization of the CD1 
molecules by clathrin vesicles. Conversely, CD1a has a short cytoplasmatic tail, without 
tyrosine motif, so it does not interact with AP-2, being internalized in a 
clathrin-independent manner [31]. After internalization, CD1b and murine CD1d interact 
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with another protein complex, AP-3 [15, 18, 31]. This one directs CD1 molecules to the 
late endossome or lysosome. CD1c and human CD1d do not interact with AP-3, being 
predominantly localized in the early and late endossomes [15, 18]. CD1a has a distinct 
distribution pattern, being localized solely in the early endossome [15, 18]. In the 
endocytic compartments, CD1 molecules are loaded with lipid antigens and then sent again 
to the plasma membrane, where they are able to stimulate T cells.  
Lipid antigens localize in certain organelles according to their biochemical 
characteristics, as lipid length, saturation and headgroups [32]. Therefore, it was speculated 
that the variability existent between the pathways followed by each CD1 isoform is 
essential to allow the encounter with the various types of lipid antigens [33]. 
 
Figure 2. CD1 isoforms present different trafficking routes. Image from [15].  
 
1.2.2. Lipid antigens 
 
Lipid antigens are mainly recognized by T cells [34]. They can be classified 
according to their origin. If the antigen is produced in the body it is called a self antigen 
and if it derives from external microbial or environmental sources (i.e. pollens), a non-self 
antigen. Surprisingly, in contrast to peptide antigens, which are mainly non-self due to 
negative selection that occurs during development of T cells, lipid specific T cells present a 
high degree of self reactivity [35, 36]. Lipid antigens can also be divided according to the 
synthesis place. A lipid antigen that is produced in the same APC that will present it is an 
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endogenous antigen, whether a lipid synthesised in other cells that is then transferred to an 
APC is called an exogenous antigen [17]. The first identified and most potent lipid antigen 
is α-galactosylceramide (α-GalCer), a synthetic glycosphingolipid that has some minor 
structural modifications from a compound originally isolated from a marine sponge [37]. 
Several glycosphingolipids of self origin were later identified as lipid antigens, such as 
GM1, sulfatide and GD3 [17]. Phospholipids can also be antigenic to CD1-restricted T 
cells. These include phosphatidylinositol, lyso-phosphatidylcholine, phosphatidylcholine 
and phosphatidylethanolamine. The last two compounds were also found in pollen and 
were capable of stimulating the proliferation of T cells from allergic patients [38]. Most of 
the non-self lipid antigens were isolated from mycobacteria and are glycosphingolipids. 
However, a lipopeptide present in mycobacteria was isolated in complex with CD1a [21].   
A lipid antigen can be presented by only one or by several isoforms of CD1 (Table 
2). Of all the self lipid antigens, sulfatide is the one with a broader CD1 binding capacity, 
since it has been identified in complexes with all antigen-presenting CD1 isoforms. 
Furthermore, sulfatide was shown to be stimulatory for T cells restricted to CD1a, b, c and 
d [17]. 
 
Table 2. Different self lipid antigens presented by specific CD1 isoforms. Adapted from [17]. 
Self antigens 
Antigen Restriction 
GM1 CD1b 
iGb3 CD1d 
GD3 CD1d 
Phosphatidylcholine CD1d, b 
Sulfatide CD1a, b, c, d 
  
 
1.2.3. Lipid antigen loading on CD1 molecules 
 
Exogenous lipids need to reach the APC to bind to CD1. Due to their hydrophobic 
properties, lipids are transported in association with low density lipoproteins, very low 
density lipoproteins and high density lipoproteins. When the lipid antigens reach the APC, 
they are internalized either by lipoprotein interaction with cell surface receptors, insertion 
in the plasma membrane or internalization of exosomes or apoptotic bodies [39]. The most 
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common process for lipid acquisition is mediated by lipoproteins. This allows specific 
delivery of the lipid antigens to the APCs. Some antigens, such as sulfatide, GM1 and 
α-GalCer do not require internalization by the APC to bind to CD1 and activate T cells [40, 
41]. However, other lipid antigens need to be internalized and processed to originate the 
antigenic form. Lipid processing takes advantage of different enzymes involved in 
lysosomal glycolipid degradation. Three lysosomal enzymes have already been implicated 
in this process: α-galactosidase A [42], β-hexosaminidase [43] and α-mannosidase [27]. 
An important issue is how lipids are extracted from lysosome membranes, digested 
by hydrolases and loaded in CD1 molecules. Lipid transfer proteins (LTPs), like saposins, 
GM2 activator protein, Niemann-Pick type 2 (NPC2) protein and CD1e are central in the 
referred processes [27, 43-46]. Saposin C is capable of extracting lipids from membranes 
and forming a complex with CD1b, thus indicating that it promotes the lipid loading in 
CD1b [44]. In fact, APCs which express CD1b but are deficient for saposin C are severely 
compromised in the ability to present lipid antigens [44]. In addition, the lack of saposins 
in mice was associated with absence of the CD1d restricted invariant natural killer T 
(iNKT) cells in the thymus, spleen and liver [43]. Furthermore, thymocytes from saposin 
deficient mice were not able to stimulate a self-reactive iNKT cell hybridoma [43]. It was 
later discovered that the most efficient saposin in loading of lipids in CD1d molecules was 
saposin B [45]. Altogether these data indicate that saposins are essential for lipid antigen 
presentation through CD1b and CD1d. GM2 activator protein is capable of removing lipids 
that are already loaded in CD1d and assists in α-GalCer loading in CD1d and [43]. NPC2 
is essential for the formation of the CD1d-lipid complex in mice [46]. This protein 
transports glycolipids to the lysosome, where they are loaded in CD1d. Mice deficient for 
NPC2 have almost no iNKT cells [46]. It was observed in vitro that NPC2 facilitates iGb3 
(isoglobotriaosylceramide) binding to CD1d, thus having similar functions to saposins 
[46]. CD1e is a LTP that has an important function in antigen presentation, helping in lipid 
processing [27]. This function was discovered by using THP cells transfected with CD1B 
and CD1E or only CD1B as APCs to activate CD1b restricted T cells [27]. While 
CD1B+CD1E cells had the ability to present the Mycobacterium antigen PIM6 to CD1b-
restricted T cell clones, cells only transfected with CD1B were incapable to present PIM6 
but had no alterations in presentation of other lipid antigens that do not require processing. 
This indicated that CD1e is a key player in lipid antigen processing. It was further 
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discovered that CD1e does not have intrinsic enzymatic activity, but it works as a co-factor 
for some lysosomal hydrolases, such as α-mannosidase [27]. 
Although LTPs play a major role in lipid loading, other factors facilitate this 
process. For example, low pH induces conformational changes in CD1 molecules, opening 
their binding pocket and thus promoting lipid binding [31].  
All these processes are essential for CD1-restricted T cells activation. 
 
1.2.4. CD1-restricted T cells 
 
CD1-restricted T cells are activated by the interaction of the TCR-CD3 complex 
with a lipid antigen bound to one of the isoforms of the CD1 molecule (Figure 3). This 
interaction initiates a cascade of signals responsible for T cell proliferation, cytokine 
production and in some cases cytolytic activity. These lipid-specific T cells can be 
classified according to what CD1 molecule they respond to, i.e. according to CD1 
restriction. Some characteristics of the different types of CD1 restricted T cells are 
presented in Table 3. 
 
Figure 3. CD1-restricted lipid-specific T cells activation by dendritic cells. 
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Table 3. Comparison between different types of CD1-restricted T cells. Modified from [47]. 
CD1d 
 CD1a CD1b CD1c 
iNKT Type II 
TCR αβ and γδ αβ αβ and γδ Vα24Jα18; Vβ11 αβ and γδ 
CD4/CD8 
CD4+, CD8+, 
DN 
CD4+, CD8+, 
DN 
CD4+, CD8+, 
DN 
CD4+, CD8+, 
DN 
CD4+, DN (mouse) 
Main lipid 
antigens 
Sulfatide 
Sulfatide, GM1, 
mycolic acid 
Sulfatide 
iGb3; α-GalCer 
and analogs 
Sulfatide; 
lysophosphatidylcholine 
 
CD1 restricted T cells can be classified in group I restricted T cells and group II 
restricted T cells, the natural killer T (NKT) cells. This section will characterize these two 
different groups. 
 
Group I CD1-restricted T cells 
Group I CD1-restricted T cells include T cells restricted to CD1a, CD1b or CD1c. 
These cells can express a variable repertoire of αβ TCRs [18]. Some studies found that 
there are also γδ T cells that recognize CD1 [17]. Regarding CD4 and CD8 expression, 
group I CD1-restricted T cells can be only positive for CD4 (CD4
+
), CD8 (CD8
+
) or 
negative for both (DN) [18]. The effector functions of these cells were mainly analysed in 
response to mycobacterial antigens. They secrete Th1, Th2 and Th17 cytokines [17]. 
Recently, a population of CD1a-restricted T cells was shown to produce IL-22 [35]. In 
addition to cytokine production, both CD8
+
 and DN CD1 restricted T cells were shown to 
be efficient cytolytic T cells, as they are able to lyse mycobacterium infected cells [17, 18]. 
The differences in cytokine production and cytolytic activity suggest that group I 
CD1-restricted T cells may be divided in distinct functional subsets. 
One of the key features of CD1-restricted T cells is self-reactivity, which is related 
to their ability to recognize self lipid antigens [35]. Although it was known that self-
reactive CD1-restricted T cells existed, their abundance was only assessed by the end of 
2010 [35, 36]. This is explained by the absence of cell surface markers that allow their 
identification. However, two recent studies have made some progress in the 
characterization of group I CD1 restricted T cells. Two different methods were used to 
assess the frequency of self-reactive group I CD1 restricted T cells. Jong and collaborators 
assessed self-reactivity by an antigen presentation assay that bypassed MHC restriction and 
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the requirement for defined antigens, using APCs with low expression of MHC molecules 
and transfected with CD1 molecules. Then, polyclonal T cells were added to the APCs. 
When CD1-restricted T cells were present they became activated and produced cytokines 
that were detected by ELISPOT [35]. In the study of de Lalla and collaborators, screenings 
of libraries of T cell clones obtained from the peripheral blood of healthy adults and 
neonates were performed. The results were confirmed using limiting dilution analysis of 
total adult T cells. Both studies found an unexpected high frequency of self-reactive CD1 
restricted T cells. In the peripheral blood of healthy adults CD1a-restricted T cells are the 
most frequent [35, 36], followed by CD1c, the group II CD1d and finally CD1b-restricted 
T cells [36]. These subsets seemed to be shaped during life, since the frequencies varied 
between blood from neonates and adults [36]. Furthermore, CD1-restricted T cells present 
a naïve phenotype at birth that persists through adulthood, with a high percentage of cells 
expressing CD45RA [36]. However, there are more CD1 reactive T cells expressing 
CD45RO in adults’ peripheral blood than in neonates’ umbilical cord blood [36]. 
Self-reactive CD1a restricted T cells were further analysed for expression of CD4 and CD8 
molecules and CD8
+
, CD4
+
 and DN cells were found [35]. Regarding TCR expression, 
there was no conservation between the different self-reactive CD1a-restricted T cells [35]. 
 
Group II CD1-restricted T cells: NKT cells 
NKT cells are self-reactive CD1d-restricted T cells that express simultaneously NK 
cells markers and the T cell receptor [48]. According to the TCR properties, NKT cells can 
be divided in two groups: type I NKT cells, or invariant NKT cells (iNKT), which express 
a TCR composed of an invariable α chain associated with a limited repertoire of β chains; 
and type II NKT cells, which have a TCR with variable α and β chains [47]. iNKT cells 
can be identified by CD1d tetramers loaded with α-GalCer or α-GalCer analogs. On the 
contrary, type II NKT cells do not recognize α-GalCer and therefore are not stained with 
this method [47]. Type II iNKT cells recognize antigens such as sulfatide and 
lysophosphatidylcholine [47]. They have an activated memory phenotype and modulate 
immune responses [47]. Some functions that were attributed to type II NKT cells include 
the suppression of autoimmunity and inhibition of tumour rejection [47]. Little information 
is available regarding type II NKT cells, since they are difficult to identify due to the 
absence of useful cell surface markers.  
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Most of the studies in the field of CD1 restricted T cells are centred in iNKT cells, 
because they can be identified by the use of CD1d tetramers. iNKT cell percentage is very 
variable among humans, ranging from values of 0.001% to over 3% of peripheral blood 
mononuclear cells (PBMCs), although usually they vary between 0.01% and 0.1% [49]. 
Functionally, these cells are involved in the innate and acquired immunity, producing large 
amounts of cytokines soon after the encounter with antigens and have cytolytic activity 
[47]. They also activate NK cells, macrophages, neutrophils, B cells and T cells. iNKT 
cells were also associated with protective and regulatory functions in tumours, infections, 
transplants and autoimmune diseases [50]. In humans, iNKT cells can be divided in three 
subsets, according to CD4 and CD8 expression [48]. They can express only CD4 (CD4
+
) 
or CD8 (CD8
+
) or lack both molecules (DN). The cytokine expression profile varies 
among the different iNKT subsets: CD4
+ 
iNKT cells produce both Th1 and Th2 cytokines 
(IFN-γ, IL-4, IL-10 e IL-13) whereas DN iNKT cells produce mainly Th1 cytokines like 
IFN-γ and very low quantities of Th2 cytokines like IL-4 [51-53]. CD8
+
 iNKT cells 
produce essentially IFN-γ [53]. The percentage of CD4/CD8 iNKT cell subsets is very 
variable between individuals. CD4
+
 and DN iNKT cells are the most common subsets in 
humans, with CD4
+
 varying between 17 and 53% and DN between 19-63% of total iNKT 
cells [54-64]. CD8
+
 population is rarer, representing 5 to 25% of the iNKT cell population 
[55, 56, 58, 61, 62]. These frequencies are altered in a variety of conditions. iNKT CD4
+ 
cell percentage was shown to be decreased in HIV infection [61] and after kidney 
transplants with no rejection [57] and increased in refractory celiac disease [54], during 
rejection of kidney transplants [57] and during Mycobacterium tuberculosis infection [58]. 
The iNKT CD4
+
 subset also tends to increase with age [59, 62]. The iNKT DN subset was 
reduced in hepatocellular carcinoma [55] and during Mycobacterium leprae infection [58]. 
Alterations in the iNKT CD8
+ 
subset included an increase in HIV infection [61] and a 
decrease in metastatic uveal melanoma [55]. 
iNKT cell development in the thymus begins with the expression of the invariable 
TCR. This event directs cells to the iNKT differentiation pathway. The cells are positively 
selected by the interaction of the TCR with CD1d molecules expressed by thymocytes. In 
mice, iNKT cell maturation is composed by at least four stages. The first is characterized 
by a population of CD24-positive, CD44
lo
NK1.1
lo
 cells. Only after CD24 downregulation 
cells start to proliferate, maintaining low expression of CD44 and NK1.1. After this stage, 
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CD44 is upregulated (CD44
high 
NK1.1
-
). At this point some cells downregulate CD4, 
constituting the DN iNKT cell lineage. The last stage is characterized by the upregulation 
of NK1.1 and other NK cell markers, which usually occurs after migration to the periphery 
[65]. In humans, iNKT cell maturation is also completed at the periphery, where cells 
increase the expression of CD161 (human equivalent to NK1.1). The earliest detectable 
NKT cell precursors in humans are CD4
+
 CD161
lo
 cells. This indicates that the CD4
-
 
population appears at later developmental stages  [47]. In humans, the origin of the iNKT 
CD4
+
 and CD4
-
 subsets at the periphery is different. iNKT CD4
+
 subset is mainly sustained 
by thymic output and survival at the periphery, while iNKT CD4
-
 subset is maintained 
essentially due to cell division that occurs in the periphery [66]. 
iNKT cells are activated when they encounter exogenous or endogenous antigens 
loaded in CD1d molecules. The activation process may occur by three different pathways, 
depending on the type of antigen [67]. In a direct pathway, the antigen is initially 
internalized and loaded in CD1d molecules or directly loaded in the CD1 molecules 
present at the cell surface. Then, the CD1d-lipid complex present at the surface of the APC 
interacts with the TCR of the iNKT cell, which causes its activation (Figure 4, direct 
pathway). Some antigens bind toll-like receptors present at the surface of the APC, starting 
a cascade of events that promotes the loading of endogenous antigens in CD1d molecules 
and IL-12 secretion. In this case, there is a double activation of iNKT cells by IL-12 and by 
CD1d interaction with TCR (Figure 4, direct + indirect pathway). There is still a third 
pathway in which there is no TCR mediated recognition of the antigen. Instead, the antigen 
only promotes IL-12 secretion by APCs (Figure 4, indirect pathway).  
 
Figure 4. Different pathways leading to iNKT cell activation during infection. Adapted from [67]. 
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1.3 CD1 restricted T cells in lysosomal storage diseases 
 
The lysosome is an important cellular compartment for lipid antigen presentation 
by CD1 and consequently for CD1 restricted lipid specific T cells. Since lysosome function 
is impaired in LSDs, lipid antigen presentation can also be defective. A problem in lipid 
antigen presentation would lead to altered CD1 restricted T cells populations. Most of the 
studies regarding lipid specific CD1 restricted T cells in LSDs were performed in mice and 
only iNKT cells were analysed. In mouse models of several LSDs there is a decrease in the 
percentage of iNKT cells in the thymus and at the periphery. This applies to Sandhoff 
disease [68-70], GM1 gangliosidosis [69, 71], NPC1 deficiency [69, 72], NPC2 deficiency 
[46, 71], Tay-Sachs disease [69], multiple sulfatase deficiency [70] and Fabry disease [42, 
69, 73] mouse models. In contrast, MPS type I, metachromatic leukodystrophy and Krabbe 
disease presented no alterations in the percentage of iNKT cells [70]. These results raised 
the question of whether this reduction in iNKT cells arises from a specific defect that leads 
to accumulation of a specific lipid or simply due to a non-specific effect of 
macromolecules accumulation in the lysosome. 
In humans, both Gaucher and Fabry disease patients were analysed regarding iNKT 
cell percentage. In Gaucher disease no alterations were found in iNKT cell percentage 
when compared to controls. There were also no differences in iNKT cell percentage when 
patients under ERT or not under ERT were compared [74]. In Fabry disease patients, no 
alterations in the percentage of iNKT cells were found [73, 75]. Fabry disease patients 
under ERT and not under ERT were also compared and no differences were detected [75]. 
Due to high individual variation of iNKT cell percentage, small alterations in iNKT cell 
percentage might not be detected. Studies that follow the percentage of iNKT cells along 
ERT at an individual level are missing and can be useful to better understand the effect of 
ERT in iNKT cell populations. No studies regarding lipid antigen presentation of either 
CD1d or group I CD1 molecules were performed in LSDs patients. 
To investigate the cause of the decrease in the percentage of the iNKT cell 
population in LSDs, the capacity of APCs from LSDs mouse models to present lipid 
antigens to iNKT cells was assessed. In the Shandhoff, Fabry, GM1 gangliosidosis, NPC1 
deficiency and NPC2 deficiency diseases it was confirmed that the reduction in the number 
of iNKT cells is associated with deficient lipid antigen presentation [42, 46, 68, 69, 71, 
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72]. In 2007, it was shown that two types of alterations can occur depending on the specific 
LSD [71]. In GM1 gangliosidosis disease mouse model, there is reduced exogenous and 
endogenous antigen presentation to iNKT cells by thymocytes, but not dendritic cells. 
When fixed thymocytes are used in presentation studies, they show normal presentation of 
both types of antigens indicating that surface expressed CD1d is functional and that it is 
forming complexes with the lipid antigen. This suggests that the defect leading to reduced 
iNKT cell percentage might be related to intracellular alterations, such as the retention of 
lipid antigens in the storage compartments. A different type of alteration was detected in 
NPC2 deficient mice. In these animals, there is altered presentation of endogenous and 
exogenous antigens by thymocytes and dendritic cells and the defect persists even when 
fixed dendritic cells were used. Furthermore, there is no formation of complexes between 
CD1d and the lipid antigen. This indicates that there is an extracellular problem, which 
could arise from the strong association of the accumulated lipids with CD1d, impairing the 
linkage of the real antigen [71].  
Recently, it was shown that dendritic cells from Fabry disease mice (α-Gal A 
deficient) induced a strong response of iNKT cells [76]. This response disappeared when 
glycosphingolipid synthesis or recognition was artificially abolished. This suggests that 
α-Gal A is important for stimulation of iNKT cells by glycosphingolipids. It was then 
observed that iNKT cells from Fabry disease animals presented signals of chronic 
stimulation at the periphery: there was increased apoptosis in liver iNKT cells, but not in 
thymus iNKT cells; the expansion of liver and spleen iNKT cells as measured by BrdU
+
 
cells was reduced; iNKT cells were less responsive to the exogenous antigen α-GalCer, 
producing lower amounts of IFN-γ than control iNKT cells. Altogether these data indicate 
that α-Gal A has an important role in the activation of iNKT cells at the peripheral level 
[76].   
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2. Aims 
 
Considering that the lysosome is an important compartment for lipid antigen 
presentation and that alterations in lipid antigen presentation in mouse models of LSD 
were already found, the main aim of this work was to study the effect of Fabry disease 
metabolic alterations in lipid antigen presentation and recognition. The more specific aims 
were: 
 
1. To quantify the subsets of the lipid specific iNKT cells, in Fabry disease patients. 
2. To test the capacity of dendritic cells from Fabry disease patients to present lipid 
antigens by the CD1 isoforms b and d. 
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3. Methods 
 
All the experimental analyses were performed using peripheral blood samples from 
Fabry disease patients and control subjects. PBMCs were isolated and used for: 1) flow 
cytometry analyses, to study the iNKT cell population; 2) dendritic cells generation. For 
patients under ERT, the analyses of the iNKT cell population were done every four 
months. For four patients, the first of the five determinations was performed by Dr Fátima 
Macedo prior to the start of this thesis. Dendritic cells were cultured for 5 days and then 
analysed by flow cytometry to confirm the success of the differentiation and to assess CD1 
cell surface expression, or used in antigen presentation assays. In these assays, dendritic 
cells were incubated with different concentrations of lipid antigen and a T cell clone 
restricted for a CD1 molecule. The capacity of antigen presentation was evaluated by the 
amount of GM-CSF produced by the activated T cells measured by enzyme linked 
immunosorbent assay (ELISA).  Figure 5 represents the experimental design used in this 
study.  
 
Figure 5. Experimental design of the study. * Every four months for patients under enzyme 
replacement therapy (ERT). 
 
Before the beginning of the patients’ analyses it was necessary to optimize some of 
the techniques that would be used. These include dendritic cell production, flow cytometry 
analyses and antigen presentation assays. 
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Subject selection and sample collection 
Seven Fabry disease patients and nine control subjects were analysed in this study. 
In the Fabry disease group, five were males and two were females. In the control group, 
there were four males and five females. Control subjects were blood donors at the Centro 
Regional de Sangue do Porto – Instituto Português do Sangue (IPS). Samples were 
obtained under a protocol between IBMC and IPS. Fabry disease patients were recruited by 
their physicians, Dr Olga Azevedo Silva from Centro Hospitalar do Alto Ave and Dr. 
Emanuel Correia from Hospital de São Teotónio. The biochemical and molecular diagnosis 
of these patients was done in our laboratory, by Daniel Rodrigues and Paulo Gaspar, under 
the supervision of Dr Clara Sá Miranda. Briefly, the biochemical diagnosis was done by 
measurement of α-Gal A activity in dried blood spot (DBS) and genotypic alterations were 
identified by molecular studies of the GLA gene using denaturating high performance 
liquid chromatography followed by DNA sequencing, as described in [12]. In the 
beginning of this study, four patients were already under ERT. This treatment consists in 
the infusion of the α-Gal A enzyme (algasidase α, Replagal, Shire HGT), every other week. 
Of the other three patients, one started treatment during the course of the study and the 
other two are not under ERT. The characteristics of the patients included in the study are 
described in the results section 4.1, on Table 7.  
Blood samples were collected in ethylenediamine tetraacetic acid (EDTA) 
containing tubes. For patients under ERT, the blood withdrawal was done before the 
enzyme infusion. 
 
Peripheral blood mononuclear cells isolation 
Upon sample arrival, PBMCs were isolated using density gradient centrifugation 
with Histopaque-1077
® 
(Sigma), under sterile conditions. The blood was layered on an 
equal amount of Histopaque-1077
® 
and centrifuged at 400xg for 30 minutes without brake. 
After the centrifugation, the PBMCs are located in a ring between the plasma and 
Histopaque-1077
® 
(Figure 6). PBMCs were then collected and washed once by adding 10 
mL of phosphate buffered saline 1x (PBS 1x, see appendix I) and centrifuged at 250xg for 
10min. Then, remaining erythrocytes were lysed by incubating cells for 10min with 10mL 
of ACK lysis solution (see appendix I). Cells were washed once more with 10 mL of PBS 
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and counted using a microscope counting chamber (Neubauer chamber). After cell count, 
PBMCs were used for flow cytometry or for dendritic cell differentiation. 
 
 
Figure 6. PBMC isolation using Histopaque 1077
®
. 
 
Flow cytometry 
Up to 1 x 10
6
 PBMCs or about 0.25x10
6
 dendritic cells were stained per well in a 
round-bottomed 96-well plate. After cell addition, plates were centrifuged at 1200 rpm, for 
2 min. For PBMCs, supernatant was rejected and cells were resuspended in 25µL of the 
antibody/tetramer mix diluted in PBS 0.2% BSA 0.1% NaN3 (flow cytometry solution, see 
appendix I). The antibodies listed in Table 4 were used.  
 
Table 4. Antibodies used in PBMCs flow cytometry to identify iNKT cells populations. 
Antibody Clone Fluorochrome Brand 
Anti-human CD3 SK7 PerCP-Cy5.5 eBioscience 
Anti-human CD4 RPA-T4 PE-Cy7 eBioscience 
Anti-human CD8 RPA-T8 APC-eFluor 780 eBioscience 
APC-eFluor 780 – Allophycocyanin conjugated with eFluor 780; PE-Cy7 – Phycoerythrin conjugated with 
Cy7; PerCP-Cy5.5 - Peridinin chlorphyll protein conjugated with Cy5.5. 
 
To identify iNKT cells, the CD1d tetramer loaded with PBS57 and labelled with 
the fluorochrome phycoerythrin (PE), from the National Institute of Health tetramer core 
facility was used. PBS57 is a recently developed analogue of α-GalCer, that was shown to 
have indistinguishable activity from α-GalCer, being the CD1d-PBS57 tetramer capable of 
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effectively detect both mouse and human iNKT cells [77]. An unloaded CD1d tetramer 
was used as a control to identify unspecific staining.  
Dendritic cells needed to be blocked to avoid unspecific staining, so they were 
resuspended in 50µL of PBS 25% human serum (see appendix I) and incubated for 20 min, 
on ice. After that, dendritic cells were washed twice by adding 100µL of flow cytometry 
solution and centrifuged at 1200 rpm, for 2 min. Then, 25µL of the antibody mix were 
added. The antibodies used for dendritic cell staining are described in Table 5. 
 
Table 5. Antibodies used in dendritic cells flow cytometry to confirm differentiation and to assess CD1 
expression. 
Antibody Clone Fluorochrome Brand 
Anti-human CD1a HI149 PE eBioscience 
Anti-human CD1b SN13 FITC Biolegend 
Anti-human CD1c L161 PerCP Biolegend 
Anti-human CD11c 3.9 PE-Cy7 eBioscience 
Anti-human CD80 2D10 APC Biolegend 
APC – Allophycocyanin; FITC – Fluorescein; PE – Phycoerythrin; PE-Cy7 – Phycoerythrin conjugated with 
Cy7; PerCP - Peridinin chlorphyll protein. 
 
  Both PBMCs and dendritic cells were incubated for 20 min, at 4ºC, in the dark. 
After incubation, PBMCs were washed three times by adding 100µL of flow cytometry 
solution, centrifuge at 1200rpm for 2 min, reject supernatant and resuspend cells. After the 
last wash, PBMCs were resuspended in 400µL of PBS 1% formaldehyde (see appendix I) 
and dendritic cells were washed twice and resuspended in 400µL of PBS 1x. Then, all 
samples where transferred to FACS tubes (Falcon, BD Bioscience). PBMCs were kept at 
4ºC in the dark and acquired in the next day. Dendritic cells were acquired in the same day 
of the staining.   
For PBMCs, up to 1x10
6
 events were acquired in a FACSCanto or FACSAria (BD 
biosciences), using the FACSDiva software (BD biosciences). In the case of dendritic 
cells, 20000 events were acquired in FACSCalibur (BD biosciences) using the Cell Quest 
software. All flow cytometry analyses were done using the FlowJo software (Tree Star).  
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Dendritic cell differentiation 
 PBMCs include lymphocytes and monocytes. Dendritic cells can be differentiated 
in vitro from peripheral blood monocytes, so it was necessary to separate the two cell 
types. This was achieved using immunomagnetic labelling with MACS anti-human CD14 
MicroBeads (Miltenyi Biotec). This technique uses magnetic
 
beads bound to an anti-
human CD14 antibody that attaches to the monocytes (that are CD14
+
 cells) (Figure 7).  
 
Figure 7. Separation of CD14+ cells by positive selection using MACS beads (Miltenyi 
Biotech). Figure adapted from http://www.miltenyibiotec.com 
 
PBMCs were washed once with 5mL of 1x PBS 2mM EDTA 0.5% BSA (MACS 
buffer, see appendix I). Then, they were centrifuged at 1800 rpm for 5 min and the 
supernatant was rejected. Cells were resuspended in MACS buffer and incubated with the 
anti-human CD14 magnetic beads, on ice, for 20 min, in the dark, with occasional shaking. 
This step allows the anti-human CD14 antibodies present in the magnetic beads to bind to 
the monocytes. The amount of MACS buffer and magnetic beads used depended on the 
total number of cells in the solution, according to the following proportion: for 100x10
6
 
PBMCs, use 475µL of MACS buffer and 62.5µL of anti-human CD14 magnetic beads. 
After incubation, cells were washed twice with 5mL of MACS buffer. Depending on the 
number of PBMCs available, MS or LS columns were chosen for isolation, according to 
the manufacture’s instructions. MS columns were used if there were less than 20x10
6
 
PBMCs available and LS columns if there were more. The columns were placed in the 
magnetic support and pre-wetted with MACS buffer. This support keeps the labelled cells 
from eluting due to the magnetic force existent between the beads and the support. Cells 
were resuspended in 4mL (always for LS columns) or 0.5mL (always for MS columns) of 
MACS buffer and applied. The monocytes that bound to the magnetic beads remained in 
the column, while the non-labelled cells eluted. The column was washed by loading 4mL 
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or 0.5mL of MACS buffer three times. This step is important to remove from the column 
cells that are not bound to the magnetic beads, increasing the efficiency of the separation. 
Finally, the column was removed from the magnetic support and placed in a 15mL falcon 
tube. 4mL or 1mL of MACS buffer were loaded in the column and then cells were flushed 
from the column to a 15mL falcon tube, by applying the plunger, supplied with the 
column. At this step, CD14
+
 cells are eluted, since the column is no longer in the magnetic 
support. After the isolation process, cells were counted and plated at 1x10
6
cells/mL in six-
well plates, 3mL per well in dendritic cell culture medium (see appendix I), containing 
25ng/mL of recombinant human IL-4 (rhIL-4, ImmunoTools) and recombinant human 
granulocyte macrophage-colony stimulating factor (rhGM-CSF, ImmunoTools). Cells 
were incubated at 37°C, 5% CO2. At day 3 of culture, medium was refreshed by removing 
500µL of culture medium per well and by adding 500µL per well of dendritic cell medium 
with a higher concentration of cytokines (75ng/ml rhIL-4 and 75ng/ml rhGM-CSF). Cells 
were used for activation assays and flow cytometry at day 5. 
 
T cell clones 
T cell clones used for the lipid antigen presentation assays were kindly provided by 
Prof. Gennaro De Libero from Basel University, Switzerland. T cell clones were 
established and maintained as described [40, 78, 79]. Briefly, T cell lines were produced by 
the stimulation of PBMCs with autologous dendritic cells that had been pre-incubated with 
a mixture of glycolipids [78]. After three weeks, growing T cells were restimulated with 
heterologous dendritic cells plus the mixture of glycolipids. T cell clones were obtained by 
limiting dilution and scored for antigen specificity and CD1 restriction using CD1-
transfected APCs [40, 78].  
Three T cell clones were used, that respond to different lipid antigen-CD1 
complexes, as described in Table 6.  
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Table 6. T cell clones used for antigen presentation assays. 
Name Specificity Restriction Reference 
GG33A GM1 CD1b [78] 
DS1C9b Sulfatide CD1b [40] 
s33d Sulfatide CD1d * 
* Description of this clone was not published yet. Clone from Gennaro De Libero laboratory. 
 
Every 3 weeks T cells need to be restimulated. T cell clones restimulation is done 
using irradiated PBMCs as feeder cells and the antigen phytohaemagglutinin (PHA) in 
medium containing recombinant human IL-2 (rhIL-2). PBMCs are isolated following the 
protocol presented above. Then, PBMCs are resuspended in culture medium (appendix I) 
at a concentration of 5x10
6
cells/mL and irradiated in a gamma irradiator (Gammacell 
1000, Nordion) at 3000 rad. After the irradiation process, cells are washed twice with 
culture medium and once with PBS. PBMCs are counted and resuspended in T cell culture 
medium (appendix I) with 2 µg/mL of PHA. The T cell clones to be restimulated are in 
culture, at a concentration of approximately 1x10
6
cells/mL, 1mL per well. For 
restimulation, 1mL of irradiated PBMCs is added to each well containing T cells. Two 
wells have only irradiated PBMCs, to verify the efficacy of the irradiation process. If the 
irradiation is successful, all irradiated PBMCs should die after approximately 15 days.   
 
Lipid antigen presentation assays 
Lipid antigen presentation assays were used to assess the capacity of dendritic cells 
to present lipid antigens by CD1 molecules. In these in vitro assays, dendritic cells are 
incubated with the lipid antigen and with T cell clones. When the T cell clones recognize 
the lipid antigen bound to CD1 at the cell surface of the dendritic cell, they start producing 
cytokines that can be then detected, indicating the efficiency of the lipid antigen 
presentation. 
These in vitro assays were performed as previously described [40, 78]. Dendritic 
cells were collected, counted and resuspended in culture medium (Appendix I) without 
inactivated fetal bovine serum (iFBS) at a concentration of 0.4x10
6
 cells/mL. This medium 
does not contain iFBS to facilitate lipid antigen uptake by the dendritic cells. 20000 cells 
(50µL of the solution of 0.4x10
6
 cells/mL) were added to each well of a 96-well flat-
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bottomed plate and incubated at 37°C, 5% CO2. Then, antigen dilutions were performed. A 
5mg/ml stock solution of sulfatide diluted in chlorophorm:methanol (2:1) was prepared. 
The highest concentration to be tested was of 30µg/ml. However, the final antigen 
concentration is diluted 4x, since 50µL of the antigen are used in a final volume of 200µL. 
Therefore, it was necessary to prepare a solution of 120µg/ml. GM1 was initially diluted in 
a solution of chlorophorm:methanol (1:1) in a concentration of 10mg/ml. The highest 
concentration to be tested was 50µg/ml. As for sulfatide, GM1 is diluted 4x in the 
activation volume, so a solution of 200µg/ml was necessary. The lipid antigens were then 
dried under N2 and dissolved only in methanol to obtain the needed concentrations, 
because chlorophorm is toxic for the cells. Then, the antigens were sonicated for 3 min in a 
water bath sonicator. Eight serial dilutions of 1:3 in duplicates were prepared in 50µl of 
culture medium without iFBS and added to the wells containing the dendritic cells. The 
lipid antigen concentrations tested were: 1) for sulfatide, 30; 10; 3.3; 1.1; 0.4; 0.1; 
0.04µg/mL and no antigen; 2) for GM1, 50; 16.7; 5.6; 1.8; 0.6; 0.2; 0.0704µg/mL and no 
antigen. Cells were incubated with the lipid antigens at 37°C, 5% CO2, for 4h. Meanwhile, 
the T cell clones were collected, washed once with PBS and counted. 100µl of culture 
medium with 20% iFBS containing 100000 T cells were added per well. This media has 
20% iFBS to obtain a final concentration of 10%iFBS, since 100µl are added in a total 
final volume of 200µl. The T cell clones, dendritic cells and lipid antigens were incubated 
for 36 hours at 37°C, 5% CO2, to allow T cells activation and cytokine production. Then, 
plates were centrifuged at 1200 rpm for 2 min and 150µL of the supernatant were collected 
and frozen or used immediately for determination of cytokine concentration by ELISA. 
 
ELISA 
Cytokine concentration determination was performed by ELISA. ELISA plates 
(MaxiSorp®, Nunc) were coated with 50µL per well of purified anti-human GM-CSF 
(BVD2-23B6, Biolegend,) at 4ºC, over night. The coating solution was then removed and 
wells were washed once by adding 300µL of washing buffer (PBS, 0.05% Tween 20; 
appendix I) to each well. Then the wells were blocked by adding 100µL of blocking buffer 
(PBS, 0.05% Tween 20, 1% BSA; appendix I) and incubated at room temperature for one 
hour. After this process, wells were washed twice and incubated with 50µL of the sample. 
In some wells, 50µL of standard rhGM-CSF were added in eight different concentrations 
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(1:3 serial dilutions starting in 20ng/mL), in duplicates. After one and a half hour, wells 
were washed three times and 50µL of the biotinilated anti-human GM-CSF antibody 
(BVD2-21C11, Biolegend) were added to each well. One hour and a half later, wells were 
washed again with washing buffer three times. For detection of the biotinilated antibody, 
70µL of streptavidin conjugated with horseradish peroxidase (Invitrogen) were added to 
each well. This compound was incubated for one hour at room temperature, in the dark. 
After washing wells four times, 90µL of SigmaFast™ o-phenylenediamine 
dihydrochloride (OPD) (Sigma), a substrate for the horseradish peroxidase, were added. 
The OPD reagent was prepared according to the manufacturer’s instructions. The reaction 
occurred for 30 minutes, at room temperature in the dark. Then 50µL of H2SO4 were added 
to stop the reaction. Absorbance was read at 490nm on an ELISA plate reader (µQuant, 
Biotek). According to the rhGM-CSF standards, absorbance values were converted to 
cytokine concentration values. 
 
Statistical analyses 
Statistical analyses were made using the GraphPad Prism 5 software. Mean and 
standard deviation values were calculated and statistical significance was assessed by 
Mann-Whitney U tests. P-values below 0.05 were considered significant. 
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4. Results 
 
4.1 Fabry disease patients and control subjects characteristics 
 
Seven Fabry disease patients and nine control subjects were included in this study. 
The α-Gal A activity at diagnosis, genetic mutation responsible for Fabry disease, sex and 
age of the patients are presented in Table 7. The range values of normal α-Gal A activity, 
shown in table 7, were determined in our laboratory by the analysis of: 120 healthy blood 
donors from IPS for DBS activity; 123 healthy blood donors from IPS for leukocyte 
activity and 12 healthy subjects for fibroblasts activity. The control group of this study was 
composed by four males and five females and had a mean age of 44 years old (standard 
deviation of ± 9). Ages of controls and patients did not differ significantly. In the Fabry 
disease patients group, four were siblings and six of them had the same mutation. As 
expected, Fabry disease male patients presented extremely low values of α-Gal A activity. 
In heterozygous females, due to random inactivation of the X-chromosome, a higher 
variation of α-Gal A activity among patients and between different tissues of the same 
patient can be observed [7]. The two female patients studied present different α-Gal A 
activities: patient number 4 has normal activity in fibroblasts, but reduced activity in DBS 
and leukocytes; patient number 7 has normal α-Gal A activity in fibroblasts and DBS and 
presents borderline values concerning leukocytes. Although the biochemical diagnosis for 
this patient was not conclusive, she presented a clinical phenotype suggestive of Fabry 
disease. Therefore, a molecular study was performed revealing a newly described 
mutation, consisting in the deletion of a glutamate in the 358 position. 
Four of the patients were already under ERT at the beginning of the study for four 
months and other three were not. One of these patients started ERT after the analysis of the 
iNKT cell populations but before lipid antigen presentation assays were performed. 
Females were not included in the lipid antigen presentation studies.  
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Table 7. Fabry disease patients and controls subjects characteristics: age, sex, α-Gal A activity 
at diagnosis and GLA mutation. 
α-Gal A activity 
Patient Sex Age 
GLA 
Mutation 
DBS 
(spot) 
Leukocytes 
(nmol/h/mg) 
Fibroblasts 
(nmol/h/mg) 
ERT 
1
a 
M 55 F113L 0 1 4 Yes 
2
a
 M 52 F113L 0.02 2 4 Yes 
3
a
 M 61 F113L 0.01 2 4 Yes 
4
a
 F 67 F113L 0.09 3 65 Yes 
5 M 40 F113L 0.01 2 4 Yes
b 
6 M 47 F113L 0 3 ND No 
7 F 49 E358del 0.33 27 91 No 
   
Reference 
values 
0.3-1.2 28-99 44-103  
 
DBS – dried blood spot; ERT – enzyme replacement therapy; M – male; F – female; ND – not done.   
 
a
 Siblings 
b 
Not under ERT when iNKT cell and subset percentage was assessed, but already under ERT when lipid 
antigen presentation assay was performed. 
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4.2 Percentage of iNKT cells and iNKT cell subsets in Fabry disease patients 
 
The percentage of iNKT cells is not altered in Fabry disease patients’ peripheral blood 
The percentage of iNKT cells was shown to be decreased in the thymus, spleen and 
liver of several mouse models of LSDs, including Fabry disease mice [42, 46, 69-72]. As 
previously described, the iNKT cell percentage in human peripheral blood is highly 
variable [47]. In this study, PBMCs were stained with an antibody anti-human CD3 and the 
human CD1d tetramer loaded with PBS57 and analysed by flow cytometry. After defining 
the lymphocyte gate in the side scatter and forward scatter plot, T cells (CD3
+
) were 
selected and the percentage of CD1d tetramer positive cells within this gate was 
determined (Figure 8). 
 
Figure 8. Quantification of iNKT cell percentage using flow cytometry. 
 
Results concerning iNKT cell percentage in Fabry disease patients and control 
subjects are presented in Figure 9A. Interestingly there was a higher variability in 
peripheral blood iNKT cell percentage among Fabry disease patients than in control 
subjects. In the control group, females tended to present higher levels of iNKT cells, as it 
was previously described [80]. In the Fabry disease group, the two females studied 
presented low iNKT cell frequencies. Overall, no statistical significant differences were 
found between the control and Fabry disease patients group in the percentage of iNKT 
cells. 
Four of the analysed patients were under ERT for four months. The comparison 
between the percentage of iNKT cells of Fabry disease patients under ERT and patients not 
treated does not reveal significant differences, in accordance to what was previously 
described [75]. However, due to the high variation of the percentage of iNKT cells in 
human blood, cross section studies with few patients may not be the best way to elucidate 
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the effect of ERT. To better assess this effect, the percentage of iNKT cells was 
determined every four months, during 12 or 16 months. Four patients that had started ERT 
four months before were included in this longitudinal study. The four patients presented 
variable values of iNKT cell percentage. In two patients, iNKT cell percentage remained 
stable during the course of the study (Figure 9B). The other two patients had alterations in 
the percentage of iNKT cells, but they did not follow a decrease or increase pattern (Figure 
9B). In the longitudinal study, sex and age do not appear to influence the effect of ERT in 
iNKT cell percentage. In conclusion, treatment with α-Gal A for 20 months did not seem to 
alter the blood iNKT cell percentage in Fabry disease patients.  
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Figure 9. iNKT cell percentage among T lymphocytes (CD3
+
). iNKT cells were identified in the gate of 
CD3
+
 cells as positive for CD1d-PBS57 tetramer. A – Comparison between iNKT cell percentage in 
Fabry disease patients and control subjects. Horizontal bars represent means. Blue dots represent 
males and pink dots represent females. For patients that were followed during ERT, the first 
determination of iNKT cell percentage is represented. B – Variation of iNKT cell percentage in four 
Fabry disease patients every four months after beginning of ERT. 
 
Alteration in the iNKT cell subsets in Fabry disease patients: decrease in the iNKT CD4
+
 
cell subset     
In humans, the iNKT cell population can be divided in three subsets according to 
the expression of CD8 and CD4 molecules: CD4
+
CD8
-
 (CD4
+
); CD4
-
CD8
+
 (CD8
+
) and 
CD4
-
CD8
-
 (DN). At the functional level, two main subsets can be defined according to 
cytokine production: iNKT CD4
+
 and iNKT CD4
-
. While iNKT CD4
+
 cells produce both 
Th1 and Th2 cytokines, iNKT CD4
-
 cells produce mainly Th1 cytokines [51-53]. The 
frequencies of iNKT CD4
+
 cells in Fabry disease patients and control subjects are 
represented in Figure 10. Age and sex did not seem to influence the percentage of iNKT 
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cell subsets in both controls and patients. Fabry disease patients had lower percentage of 
iNKT CD4
+
 cells in comparison with control subjects (p<0.05). Interestingly, one patient, 
which was not under treatment, presented frequencies of iNKT CD4
+
 cells even higher 
than most of the control subjects. In a subsequent analysis of the same patient, after the 
beginning of ERT, the percentage of these cells remained elevated. This is the same patient 
that presented the lowest percentages of iNKT cells.  
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Figure 10. Percentage of iNKT CD4
+
 subset is reduced in Fabry disease patients. A– 
Representative example of iNKT CD4/CD8 subsets percentage determined by flow cytometry, showing 
each subset percentage in a Fabry Disease patient (left) and a control subject (right).  B– Frequencies 
of iNKT CD4
+
 subset cells in Fabry disease patients and control subjects. Horizontal bars represent 
means. Blue dots represent males and pink dots represent females. For patients that were followed 
during ERT, first determination is represented. Statistical significance was calculated by 
Mann-Whitney U test, p<0.05. 
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 It was then assessed whether ERT could reverse the reduction in the percentage of 
iNKT CD4
+
 subset in a longitudinal study. As for iNKT cell percentage, four patients were 
analysed. The results obtained, presented in Figure 11, show that two patients had constant 
percentages of CD4
+
 iNKT cells subset while two had variations in the percentage of this 
subset. Therefore, the percentage of iNKT CD4
+
 cells in these four patients did not present 
major alterations along the 20 months of treatment. As for iNKT cell percentage, age and 
sex did not seem to have an influence in the effect of treatment in the iNKT CD4
+ 
subset. 
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Figure 11. Variation of CD4
+
 iNKT cell percentage in four Fabry disease patients along 16 or 
12 months of ERT. iNKT cells were identified in the gate of CD3
+
 cells as positive for CD1d-PBS57 
tetramer and then analysed according to CD4 and CD8 expression. 
    
 The results regarding the other subsets of iNKT cells are presented in Figure 12. 
Both sex and age did not seem to have an effect on both the iNKT DN and CD8
+
 subsets. 
Fabry disease patients tended to have higher percentages of both populations when 
compared to control subjects (Figure 12A and B). However, these alterations were not 
statistically significant. When iNKT CD8
+
 and iNKT DN cells are coupled in a iNKT 
CD4
- 
subset, statistically significant differences (p<0.05) between control subjects and 
Fabry disease patients were found (data not shown).  
 
 39 
Fabry Control
0
20
40
60
80 No ERT
ERT
%
 i
N
K
T
 D
N
Fabry Control
0
10
20
30
40
50 No ERT
ERT
%
 i
N
K
T
 C
D
8
+
BA
Figure 12. iNKT subsets percentage in control subjects and Fabry disease patients. Horizontal bars 
represent means. A – iNKT DN cell percentage; B – iNKT CD8
+
 cell percentage. Blue dots represent 
males and pink dots represent females. For patients that were followed during ERT, first 
determination is represented. 
 
 The effect of ERT on the iNKT DN and CD8
+
 subsets was also assessed in the 
longitudinal study and the results are shown in Figure 13. There was high variation in the 
percentage of the iNKT DN subset during the time of the study. On the contrary, there 
seems to be a reduction in the amount of CD8
+
 iNKT cells. All patients decreased CD8
+
 
iNKT cell percentage after the first 8 months of treatment. Patients’ age and sex did not 
seem to alter the effect of ERT on the iNKT DN and CD8
+
 subsets.  
0 5 10 15 20 25
0
5
10
15
20
25
3
4
2
1
Months of treatment
%
 i
N
K
T
 C
D
8
+
0 5 10 15 20 25
40
50
60
70
80
90
3
4
2
1
Months of treatment
%
 i
N
K
T
 D
N
A B
Figure 13. Variation of iNKT DN (A) or CD8
+
 (B) cell percentage in four Fabry disease patients along 
12 ou 16 months of ERT. iNKT cells were identified in the gate of CD3
+
 cells as positive for 
CD1d-PBS57 tetramer and then analysed according to CD4 and CD8 expression. 
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4.3 Dendritic cell CD1 expression 
 
To test Fabry disease patients’ capacity to present lipid antigens through CD1 
molecules, dendritic cells were generated from Fabry disease patients’ monocytes. After 
five days of culture, dendritic cells were analysed by flow cytometry to confirm the 
dendritic cell differentiation (CD11c and CD80 expression) and to assess the cell surface 
expression of Group I CD1 molecules. In all experiments, dendritic cells had a CD80 and a 
CD11c expression compatible with dendritic cell differentiation (Figure 14). 
 
Figure 14. Representative example of monocyte derived dendritic cell CD80 (A) and CD11c 
(B) cell surface expression. Cells were stained with anti-human CD80 and CD11c and analysed by flow 
cytometry. Tinted line corresponds to unstained and black line to stained sample. 
 
Five Fabry disease patients’ (numbers 1, 2, 3, 5 and 6) and seven control subjects’ 
dendritic cells were tested for cell surface expression of all group I CD1 molecules. In this 
section are shown representative examples of the results obtained. Complete data of CD1 
expression in Fabry disease patients is available in appendix II. 
Regarding CD1a, three patients (1, 5 and 6), two of which are under ERT, 
presented no alteration in dendritic cell surface expression (Figure 15A and appendix II-
Figure S1). The other two patients (2 and 3), both under ERT, had a slight increase in the 
cell surface expression of CD1a (Figure 15B and appendix II-Figure S1) when compared 
to healthy subjects. The two patients that presented an increase in CD1a expression were 
tested again approximately two months later and the result was identical (data not shown). 
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Figure 15. Examples of CD1a expression at the cell surface of dendritic cells from control 
subjects and Fabry disease patients analysed by flow cytometry. A – No differences between control 
and patient; B – Higher expression of CD1a in patients. For other patients’ data see appendix II. 
 
The results obtained for CD1b were similar to those of CD1a, with the same two 
patients showing increased CD1b expression and the other three presenting no differences 
(Figure 16 and appendix II-Figure S2). However, when the two patients with altered 
expression were tested once more, the difference in CD1b expression decreased or even 
disappeared (data not shown).  
 
Figure 16. Examples of CD1b expression at the cell surface of dendritic cells from control 
subjects and Fabry disease patients analysed by flow cytometry. A – No differences between control 
and patient; B – Higher expression of CD1b in patients. For other patients’ data see appendix II. 
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No differences were found in the dendritic cell surface expression of CD1c. The 
five patients expressed nearly the same amount of this molecule in comparison with the 
respective controls, as shown in Figure 17 and appendix II-Figure S3. 
 
 
Figure 17. Example of CD1c expression at the cell surface of dendritic cells from control 
subjects and Fabry disease patients analysed by flow cytometry. No differences are present between 
patients and controls. For other patients’ data see appendix II. 
 
In this study, only Group I CD1 molecules were tested. This is justified by the fact 
that monocyte derived dendritic cells cultured in media containing FBS do not express 
CD1d at the cell surface in amounts detectable by flow cytometry [20].  
According to these results, there are no major differences in CD1 molecules 
expression at the dendritic cell surface between control subjects and Fabry disease patients. 
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4.4 Lipid antigen presentation to T cells 
 
The capacity of Fabry disease patients’ dendritic cells to present lipid antigens and 
activate T cells in comparison to control subjects was assessed using an in vitro system of 
lipid antigen presentation. Briefly, monocyte derived dendritic cells were incubated with 
different concentrations of lipid antigen for four hours. Then, T cell clones, restricted to 
one of the CD1 molecules, were added and incubated for 36 hours, to allow activation of 
the T cell clones and consequent cytokine production. Finally, supernatant was collected 
and cytokine concentration was determined by ELISA. The amount of cytokine produced 
is related to the efficiency of the lipid antigen presentation by CD1 molecules. Two CD1 
molecules, CD1b and CD1d, were tested. Five patients were tested for CD1b and four for 
CD1d. At the time of the lipid antigen presentation assays, patient 1 was under ERT for 
twelve months, patients 2 and 3 were under ERT for twenty months, patient 5 was under 
ERT for five months and patient 6 was not under ERT.  
 
Lipid antigen presentation by CD1b  
 Lipid antigen presentation by CD1b was studied using two different self-antigens: 
sulfatide and GM1. To test the two different antigens, two CD1b-restricted T cell clones 
were needed: DS1C9b (sulfatide specific) and GG33A (GM1 specific). As shown in Figure 
18, Fabry disease patients did not present differences in sulfatide presentation by dendritic 
cell CD1b.  
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Figure 18. GM-CSF production by T cell clone DS1C9b activated with dendritic cells from a control 
subject or a Fabry disease patient. Dendritic cells were challenged with sulfatide for 4h and then the T 
cell clone was added to the culture. Supernatant was collected 36h later and cytokine concentration 
determined by ELISA. Values represent the Mean ± Standard deviation (SD) of duplicates. 
 
 Interestingly, when the presentation of GM1 by CD1b was studied in four patients, 
two Fabry disease patients showed reduced capacity of presentation (Figure 19). This 
difference was present already at the lowest concentration of antigen tested. Patient 2 had 
no alterations in antigen presentation and a forth patient appear to induce a stronger 
activation of T cells than the control subject. However, this was only verified for higher 
antigen concentrations and in this assay the control subject presented values of cytokine 
production below the ones obtained in the other three assays. Therefore, this patient will be 
again analysed. The alterations observed in GM1 presentation do not seem to be related 
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with age. Of the two younger patients (5 and 6), one presented a higher and the other a 
lower capacity of antigen presentation than the control subject.   
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Figure 19. GM-CSF production by T cell clone GG33A activated with dendritic cells from 
control subjects or Fabry disease patients. Dendritic cells were challenged with GM1 for 4h and then 
the T cell clone was added to the culture. Supernatant was collected 36h later and cytokine 
concentration determined by ELISA. Values represent the Mean ± SD of duplicates.   
 
The presence of higher variability in the presentation of the antigen GM1 in 
comparison to sulfatide by CD1b indicates that the accumulation of Gb3 in dendritic cells 
might have different influence in the presentation of different lipids by the same CD1 
isoform. 
 
Lipid antigen presentation by CD1d 
 Results of lipid antigen presentation by CD1d are presented in Figure 20. For this 
CD1 molecule, only the antigen sulfatide was tested. Sulfatide presentation was decreased 
in two Fabry disease patients and was similar in other two, when compared to normal 
subjects. The two patients that presented reduced ability to present sulfatide are the 
younger patients. At the time of the assay, patient 5 was under ERT for only five months 
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and patient 6 was not under ERT. Patients 2 and 3 were already under ERT for twenty 
months. Therefore, it is possible that treatment has an effect on lipid antigen presentation. 
The reduced capacity of CD1d to present sulfatide in the patients 5 and 6 does not appear 
to relate with the results obtained regarding iNKT cell percentage or the percentage of 
iNKT cell subsets. Despite the very low iNKT cell percentage of patient 5, patient 6 was 
one of the subjects with higher percentages of iNKT cells.  
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Figure 20. GM-CSF production by T cell clone s33d activated with dendritic cells from control 
subjects or Fabry disease patients. Dendritic cells were challenged with sulfatide for 4h and then the T 
cell clone was added to the culture. Supernatant was collected 36h later and cytokine concentration 
determined by ELISA. Values represent the Mean ± SD of duplicates. 
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5. Discussion 
 
The lysosome is a key intracellular compartment for lipid antigen presentation and 
consequently plays an important role in the biology of CD1 restricted lipid specific T cells. 
Since in LSDs there is accumulation of undegraded macromolecules in the lysosome, it 
was hypothesized that lipid antigen presentation and thus CD1 restricted lipid specific T 
cells could be affected in LSDs. This issue was studied mainly by analysing the iNKT cell 
percentage in mouse models, since these cells are the only CD1 restricted T cells that can 
be easily detected. It was found that iNKT cells are decreased in the thymus, spleen and 
liver of various mouse models of LSDs, including in Fabry disease mice [46, 69-71]. 
Besides the low number of iNKT cells, it was also shown that Sandhoff, GM1 
gangliosidosis, NPC1 and NPC2 deficiency mouse models have a decreased capacity to 
present lipid antigens to iNKT cells [46, 69, 71, 72]. iNKT cell percentage was also 
assessed in Fabry disease patients, but no alterations were found [73, 75]. 
In this study, we aimed to investigate the CD1 restricted lipid specific T cells and 
the process of lipid antigen presentation in Fabry disease patients. For this, we analysed the 
percentage of iNKT cells and the iNKT cell subsets in Fabry disease patients. Moreover, 
lipid antigen presentation assays were performed to evaluate the capacity of Fabry disease 
patients’ dendritic cells to present lipid antigens by CD1b and CD1d.    
 
5.1 iNKT cells and their subsets in Fabry disease patients 
 
In accordance with the results previously described, in this study, no differences in 
iNKT cell percentage between control and Fabry disease patients were found [73, 75]. In 
the Fabry disease mouse model, it was described that iNKT cells are reduced in the 
thymus, spleen and liver [42, 69, 73]. This apparent discrepancy can be explained by our 
preliminary data obtained with the Fabry disease mice model. During the last year, besides 
the work presented in this thesis, I had the opportunity to collaborate in the study of iNKT 
cells present in different organs of the Fabry disease mouse model. Our results corroborate 
the previously described decrease in the iNKT cell percentage in the thymus, spleen and 
liver. However, we found no differences in the percentage of iNKT cells present in the 
lymph nodes and blood between Fabry disease and wild-type mice (Macedo et al, 
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unpublished results). The different effect of the metabolic alterations present in Fabry 
disease mice on the iNKT cells present in different organs can be explained by: altered 
traffic of iNKT cells; the difference in the organs lipid content and the presence of 
different APCs in different organs [50].  
It was previously described that age and sex have an influence in iNKT cell 
percentage. The percentage of iNKT cells decreases with age [59, 62], and females tend to 
have more iNKT cells [80]. In the control group of our study, females tended to present 
higher iNKT cell percentages than males. The two Fabry disease females analysed 
presented low values of iNKT cells. However, due to low number of patients, it is still 
early to conclude about the effect of age and sex on the iNKT cells in Fabry disease 
patients.  
In humans, iNKT cells can be divided in different subsets according to CD4 and 
CD8 expression. They can express only CD4 (CD4
+
), only CD8 (CD8
+
)
 
or none of the 
molecules (DN). Regarding the iNKT cell subsets, Fabry disease patients presented lower 
values of iNKT CD4
+
 cells and an increase in iNKT CD4
-
 cells in comparison to control 
subjects. However, the conventional CD4
+
 T cells were not decreased (data not shown). 
This indicates that the defect in the CD4
+
 subset is specific for iNKT cells. The alterations 
in the iNKT cell subsets in Fabry disease patients are corroborated by our results with the 
Fabry disease mouse model. In the Fabry disease mouse model, a reduction in the 
CD4
+
/CD4
-
 iNKT cell ratio was observed in spleen, liver, lymph nodes and blood but not 
in the thymus (Macedo et al, unpublished results).  
It was described that the iNKT cells tend to decrease and that the iNKT CD4
+
 
subset tends increase with age [59]. In this sample, no age related difference in iNKT 
CD4
+
 cells was found. However, a broader age range of Fabry disease patients needs to be 
analysed to evaluate the effect of age on the CD4
+
 iNKT cell subset. One of the younger 
patients tested presented unusually high percentages of the iNKT CD4
+
 subset. This was 
the same patient that presented the lowest values of iNKT cells. In fact, it was described by 
Montoya et al, that the percentage of iNKT cells and the percentage of the iNKT CD4
+
 
subset are inversely correlated [80]. The reduction in the iNKT CD4
+
 subset is associated 
with higher values of iNKT cells presented by three of the patients, however, other three 
patients’ still present low levels of iNKT cells with a reduction in the iNKT CD4
+
 subset.  
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It is known that iNKT CD4
+
 cells produce both Th1 and Th2 cytokines, while 
iNKT CD4
-
 produce mainly Th1 cytokines. Therefore, it is possible that Fabry disease 
patients present a bias towards Th1 cytokines. This bias would lead to a pro-inflammatory 
status that can be related to Fabry disease pathology. It was previously described that the 
presence of inflammation worsens the prognosis of patients with chronic kidney disease, 
that can also arise in Fabry disease [81]. Moreover, the inflammation marker C-reactive 
protein was shown to have a damaging effect on endothelial cells, one of the cell types 
most affected in Fabry disease [81]. 
Several factors can be involved in the reduction of the iNKT CD4
+ 
subset. 
Signalling through the TCR was shown to be important in the CD4-CD8 lineage 
differentiation of T cells in vivo. CD4 differentiation requires a prolonged TCR signal that 
needs to be present when cells start downregulating CD8. Otherwise, cells will enter the 
CD8 and not the CD4 lineage [82]. It was shown that iNKT cell development requires 
stronger signals than conventional T cells through the TCR, and that this signalling also 
seems to be important for differentiation of the iNKT CD4
+
 subset [83]. Whereas the iNKT 
CD4
+
 subset is mainly supported by thymic output and survival at the periphery with 
limited cell division, iNKT CD4
-
 cells expansion occurs mainly in the periphery [66]. 
Moreover, the factors that are responsible for iNKT cell survival in the periphery vary 
between the subsets [66]. Some factors are involved in the expression of CD4 and 
repression of CD8 during the differentiation of CD1d-restricted CD4
+
 iNKT cells. These 
include the transcription factors PLZF, GATA3 and ThPOK [84, 85]. Of those, PLZF is 
the one specific for iNKT cell development [85]. Experiments in PLZF knockout mice 
showed a selective defect in the iNKT cell development. These cells were reduced by 90-
99% in the thymus, spleen and liver while other lymphocyte populations were preserved. 
Furthermore, the residual population of iNKT cells found in the spleen presented an 
increase in the proportion of iNKT DN cells, suggesting a role of PLZF in the maintenance 
of CD4 expression [85]. An alteration in one of these factors could be responsible for the 
iNKT CD4
+
 subset reduction. Other conditions in which iNKT CD4
+
 subset reduction was 
described in humans include HIV infection, type I diabetes mellitus, long-term rejection 
after kidney transplant and acute tubular necrosis after kidney transplant [57, 60, 61]. 
Interestingly, renal pathology is also one of the symptoms of Fabry disease. 
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ERT for twenty months had apparently no effect in the percentage of iNKT cells, in 
the four patients tested. These results are in agreement with the ones obtained by 
Rozenfeld et al, which did not found differences in iNKT cell percentage between Fabry 
disease patients not under and under treatment [75]. The same was verified for iNKT CD4
+
 
and DN subsets. However, it seems that iNKT CD8
+
 cells are reduced with the treatment. 
All patients decreased iNKT CD8
+
 cell percentage after the first months of treatment. It is 
necessary to continue the study and to include more patients in order to verify the effect of 
treatment in this subset.    
 
5.2 Lipid antigen presentation by dendritic cells from Fabry disease patients 
 
Despite the several studies on lipid antigen presentation in LSDs mouse models, 
herein, for the first time, lipid antigen presentation was analysed in LSDs patients, namely 
Fabry disease patients. Patients’ dendritic cells generated from peripheral blood monocytes 
were used as APCs. The expression of group I CD1 molecules was analysed by flow 
cytometry. The Fabry disease patients tested presented no major differences in group I 
CD1 molecules cell surface expression in comparison to controls. However, two patients 
had slightly higher levels of CD1b and CD1a dendritic cell surface expression. For CD1b 
this small increase in CD1b cell surface expression did not have an effect on lipid antigen 
presentation capacity. CD1d cell surface expression was not detectable by flow cytometry. 
It was previously described that when dendritic cells are differentiated from monocytes in 
medium containing FBS, CD1d expression is downregulated [20]. It is possible to detect 
CD1d surface expression if the FBS is replaced by human serum, but there is 
downregulation of group I CD1 molecules.  
To investigate lipid antigen presentation by Fabry disease dendritic cells, an in vitro 
study was prepared that was based in the co-culture of dendritic cells, lipid antigen and 
CD1-restricted T cells. The presentation through CD1b and CD1d was evaluated. 
Regarding CD1b presentation, two antigens were tested. When sulfatide was used, control 
subjects and patients presented similar levels of T cell activation, indicating that lipid 
antigen presentation was similar for both groups. However, when the antigen GM1 was 
used, higher variation was obtained in the results. While a patient promoted T cell 
responses stronger than the control, two other patients were less efficient in antigen 
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presentation than controls. Differences obtained with the antigen GM1 but not with 
sulfatide would suggest that CD1b molecules are functional and that there is some 
alteration related to the specific lipid that is being presented. This could be related with the 
different internalization pathways followed by GM1 and sulfatide. Sulfatide is internalized 
in a clathrin dependent way whether GM1 is internalized by caveolae [21]. 
Concerning presentation through CD1d, there were two patients that induced 
weaker T cell activation than controls. The other two patients presented no alterations in 
comparison to controls. It was expected to find a relationship between the efficacy of 
presentation by CD1d and iNKT cell percentage. In fact, the patient that presented lowest 
values of iNKT cells was also the one that had lower capacity of presenting antigens in 
comparison with the control subject, regarding presentation through CD1d. However, the 
other patient with reduced lipid antigen presentation had high levels of iNKT cells. While 
the patients that did not present alteration in antigen presentation through CD1d, patients 
number 2 and 3, were under ERT for 16 months, patient 5 was only being treated for 4 
months and patient 6 was not under treatment (the two patients with reduced lipid antigen 
presentation capacity). It is possible that treatment is influencing the lipid antigen 
presentation capacity of the patients’ dendritic cells, but it is necessary to analyse more 
patients. The two patients with lower capacity of antigen presentation in comparison to 
control subjects were also the younger patients. 
Four of the five patients were already under ERT at the beginning of the study. 
ERT was shown to decrease the plasma levels of Gb3 accumulation within three months of 
treatment [14]. Therefore, it is possible that the reduction in lipid accumulation due to ERT 
corrects some defects in the lipid antigen presentation. For this reason, it is important to 
analyse patients that are not under ERT. 
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6. Conclusion and Future Perspectives 
 
This study allowed the characterization of iNKT cell CD4/CD8 subsets in Fabry 
disease patients. A reduction in the iNKT CD4
+
 subset in Fabry disease patients was 
described. This result is confirmed by the Fabry disease mouse model, which also presents 
a reduction in the iNKT CD4
+
 cells (unpublished results, Macedo et al). Due to the 
different cytokine production profile of the human iNKT cell subsets, it would be 
interesting to analyse iNKT cell cytokine production in Fabry disease patients, to verify if 
there is a bias towards Th1 cytokines, as suggested by the decrease in the iNKT CD4
+
 
subset. The effect of ERT on iNKT cell subsets was also assessed. With the exception of 
iNKT CD8
+
 cells, it did not seem to promote recovery from the imbalances initially 
observed. iNKT CD8
+
 cells apparently decrease with ERT. To confirm this result it is 
important to continue the study in these patients and to include new subjects that are still 
not under ERT. No alteration in iNKT cell percentage in the peripheral blood of Fabry 
disease patients was found in comparison to controls. Our preliminary results in the Fabry 
disease mice model show that there are also no alterations in Fabry disease mice blood, 
despite the reduction in the thymus, spleen and liver. Therefore, it would be important to 
assess the impact of the metabolic alterations present in the Fabry disease mouse model in 
the iNKT cells percentage in different organs.  
It was possible to conclude that group I CD1 molecules are normally expressed at 
the cell surface of dendritic cells. It would be interesting to analyse the expression of CD1d 
at the cell surface of dendritic cells, culturing them with human serum instead of FBS. 
Regarding lipid antigen presentation by CD1b, two different antigens were tested: sulfatide 
and GM1. With the antigen sulfatide it was observed that dendritic cells from Fabry 
disease patients are able to present this antigen by CD1b as well as dendritic cells from 
control subjects. Interestingly there was more variation when the antigen GM1 was 
presented by CD1b, which could be related to different internalization pathways of the two 
antigens. It would be interesting to test more antigens that are presented through CD1b, 
both self and non-self antigens. However, these assays are dependent on the availability of 
T cell clones specific for the various antigens. It is also important to test the lipid antigen 
presentation through the other two CD1 isoforms (CD1a and CD1c) to evaluate if lipid 
accumulation equally affects all CD1 isoforms. Moreover, it would be interesting to test 
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APCs other than dendritic cells, since several studies in mice found differences in lipid 
antigen presentation when splenocytes or thymocytes were used as APCs in lipid antigen 
presentation assays, in comparison to dendritic cells [69, 71]. Since B cells express CD1c 
and CD1d and monocytes express CD1d, it is possible to use them in lipid antigen 
presentation assays to assess if lipid accumulation equally affects APCs capacity to present 
lipid antigens. 
The pathophysiology of LSDs remains largely unknown. Moreover, a relationship 
between the molecular basis of the disease and the biochemical and clinical features has 
been hard to establish. With the study of lipid antigen presentation in these diseases, we 
hope to contribute for the better understanding of the influence of the diverse LSDs 
metabolic defects in the process of lipid antigen presentation. 
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Appendix I – Composition of the solutions used in the experimental work 
 
ACK lysis solution 
For a final volume of 500mL, add 4.15g of NH4Cl and 0.5g of KCO3 to H2O. Adjust pH to 
7.2. 
 
Culture media: 
• Culture medium: 
500 mL RPMI 1640 (Invitrogen) 
5mL of non essential aminoacids (Invitrogen)  
5mL of kanamycin (Invitrogen) 
5mL of sodium piruvate (Invitrogen) 
50mL (10%) of inactivated fetal bovine serum (Invitrogen) 
  
• Dendritic cell culture medium 
Culture medium plus 25ng/mL of rhGM-CSF (immunoTools) and rhIL-4 
(immunoTools). 
 
• T cell culture medium 
500 mL RPMI 1640 (Invitrogen) 
5mL of non essential aminoacids (Invitrogen)  
5mL of kanamycin (Invitrogen) 
5mL of sodium piruvate (Invitrogen) 
25mL of human serum (Invitrogen) 
500µL of rhIL-2 (stock 10000U/mL) (Invitrogen) 
 
Flow cytometry solution (PBS 0.2% BSA 0.1%NaN3) 
For 100mL of solution add 0.2g of bovine serum albumin (BSA) and 0.1g of NaN3 to PBS 
1x.  
 
MACS buffer 
Add 5mL of PBS, 2 mM EDTA, 5% BSA to 45mL of PBS 2 mM EDTA. 
 
• PBS, 2 mM EDTA 
2mL of EDTA 0.5 M 
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50mL of PBS 10x 
448mL of H2O 
 
• PBS, 5% BSA, 2 mM EDTA 
For a final volume of 50mL add 2.5g of BSA to PBS, 2 mM EDTA. 
 
PBS 10x 
For a total volume of 1000mL, add: 
80g of NaCl 
2g of KCl 
6.09g of Na2HPO4  
2g of KH2PO4 
 
Adjust pH to 7.3 
 
PBS 1x 
For 500mL, add 50mL of PBS 10x to 450mL of H2O.  
 
PBS 1% formaldehyde 
For a final volume of 4 mL add 1mL of 16% formaldehyde to 3mL of PBS 1x.  
 
PBS 25% HS 
For a final volume of 1mL add 250µL of human serum to 750µL of PBS 1x 
 
ELISA solutions: 
 
• Washing buffer (PBS 0.05% Tween20) 
For 100mL, add 50µL of Tween20 to PBS 1x. 
 
• Blocking buffer (PBS 0.05% Tween20, 1% BSA) 
For a final volume of 100mL, add 50µL of Tween20 and 1g of BSA to PBS 1x.  
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Appendix II – CD1 molecules expression at the surface of dendritic cells 
 
CD1a: 
 
Figure S1. Histogram plots of CD1a expression at the cell surface of DC’s from control subjects and 
FD patients. Dendritic cells were differentiated from monocytes and flow cytometry analysis of CD1 
surface expression was performed at day 5 of culture. 
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CD1b: 
 
 
Figure S2. Histogram plots of CD1b expression at the cell surface of DC’s from control subjects and 
FD patients. Dendritic cells were differentiated from monocytes and flow cytometry analysis of CD1 
surface expression was performed at day 5 of culture. 
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CD1c: 
 
Figure S3. Histogram plots of CD1c expression at the cell surface of DC’s from control subjects and 
FD patients. Dendritic cells were differentiated from monocytes and flow cytometry analysis of CD1 
surface expression was performed at day 5 of culture. 
